Nemes Rush Group’s Genmab GMAB Stock Holding History

Nemes Rush Group’s Portfolio GMAB Stock Details GMAB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-60	Closed	-$1.24K	–	701
2025 Q2	$1.24K	Buy	+60	New	+$1.23K	﹤0.01%	637

Other funds holding GMAB

OAG

Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return

Harding Loevner Bridgewater, New Jersey $9.72B AUM 22.38% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Nemes Rush Group's GMAB Position: Q3 2025 in Review

Nemes Rush Group sold out of Genmab (GMAB) in Q3 2025, closing a stake of 60 shares — an estimated $1.24K sold.

Nemes Rush Group first reported a position in GMAB in Q2 2025 and held it in 1 quarter. The position peaked at $1.24K in Q2 2025. 252 funds tracked by Wall St. Rank hold GMAB as of Q3 2025.

Nemes Rush Group reported no remaining Genmab position as of Q3 2025 after selling out during the quarter.
Nemes Rush Group sold 60 Genmab shares in Q3 2025, an estimated $1.24K.
Nemes Rush Group first reported a position in Genmab in Q2 2025 and held it in 1 quarter.
Nemes Rush Group's Genmab position peaked at $1.24K in Q2 2025.
252 funds tracked by Wall St. Rank held Genmab as of Q3 2025.

Based on Nemes Rush Group's 13F filing for Q3 2025, filed 13 Nov 2025.